Russia initiated aggression against Ukraine in 2014. On February 24, 2022, it started a full-scale military invasion to the Ukrainian territory. This brutal war and military crimes of Russian troops caused a humanitarian crisis in Ukraine with thousands civilians killed and millions becoming refuges. As a reaction to this act of aggression, many international companies decided to leave the Russian market, while some others continue doing business there as usual. We track such decisions of companies and urge them to stop funding the war.
Hold off investments: company postponing future planned investment/development/marketing while continuing substantive business
Pausing InvestmentsReducing Activities: company scaling back some business operations while continuing others
Scaling BackPause operations: company temporarily curtailing operations while keeping return options open
SuspensionClean Break: the company completely halting Russian engagements or exiting Russia
WithdrawalExit Completed: company sold its business/assets or its part of the business to a local partner and leaved the market
Exit CompletedThe company promised to stop new investments in Russia. It is continuing to work in Russia, and are taking all required measures to ensure an uninterrupted supply of medicines. Despite the statements of international pharmaceutical companies about the suspension of new tests in Russia after the start of military operations in Ukraine, the British-Swedish AstraZeneca will conduct a study of a new drug for the prevention of COVID-19 in the Russian Federation, which is necessary before its registration.
The company promised to stop any new spending not related to the supply of the essential and life-changing medicines and vaccines in Russia, as well as in Belarus. Increased revenue, profit and assets in Russia in 2022 vs 2021. Customs data shows that the latest deliveries were in 2023. Sanofi experiencing serious supply problems from its Russian plant to EU market.
Still operating in Russia. Paid $42 mn of taxes in 2022.
Teva in Russia is working in its standard operating mode
Received revenues in Russia in 2022.
Will continue to supply essential medicines, vaccines, medical devices, and equipment in Russia. Halted clinical trials, advertising, and promotion. Russian sales proceeds to go to humanitarian aid (no manufacturing and little raw materia/suply chain reliance). Still operating in Russia with increasing sales and profit volumes in 2022 vs 2021. After the start of Russia's war against Ukraine, the volume of product exports to Russia increased.
(Office in Russia)
Have decided to suspend any investment in Russia as well as commercial marketing activities. The company did not stop working in Russia. The Russian website is working. In October 2023, the general director was changed. Staff are being recruited.
Still operating in Russia
Continue to supply patients, not for fianacial reasons
Company was originally founded in St. Petersburg, over $60 milllion exports to Russia after February 24, 2022. In 2022 $28 million exports to Russia, or 28% of that year revenue. Increased revenue and profit in 2022 vs 2021.
No relevant news about leaving Russia.
Russian website works
No official statement
Business as usual
Italy's Recordati boosted by strong sales in Russia. Italian drug maker Recordati benefited from strong demand in markets such as Turkey and Russia in the first three months of the year, its chief executive said on May 11, 2023 after the company lifted its annual revenue and profit targets. Koremans said that Recordati did not produce any products in Russia but continued to import treatments for rare diseases, as well as prescription drugs for more routine conditions.
No official statement
Received revenues in Russia in 2021, there is no any official announcement
Significantly increased revenue, profit and taxes paid in Russia in 2022 vs 2021.
No official statement
Received revenues in Russia in 2021, there is no any official announcement
No official statement
A subsidiary of the Indian Jodas Expoim, filed a lawsuit in the Arbitration Court of the Moscow Region to oblige the Iranian AryoGen Pharmed to supply the drug.
Продовжують працювати як зазвичай.
No official statement
Received revenues in Russia in 2021, there is no any official announcement
Group's financials says considers Russia a main market. Revenue and profit skyrocketed in 2022 vs 2021.
No official statement
Continue doing business as usual.
Received revenues in Russia in 2021, there is no any official announcement
No official statement
Continue doing business as usual.
Still operating in Russia
The pharma giant Grindeks exporting to Belarus, whereas its subsidiary Kalceks exports to Russia. Grindeks' turnover in 2022 was EUR 258 million, of which EUR 70.6 in Russia.
Continue doing business as usual.
Received revenues in Russia in 2021, there is no any official announcement
No official statement
No official statement
Continuing business in Russia and exports. Customs data shows that the latest deliveries were in 2023.
Continues sales in Russia
No official statement
Received revenues in Russia in 2021, there is no any official announcement
No official statement
Received revenues in Russia in 2021, there is no any official announcement
Continue doing business as usual.
Received revenues in Russia in 2021, there is no any official announcement
Received revenues in Russia in 2021, there is no any official announcement
Still operating in Russia.
No official statement
No official statement
SA's Aspen to keep supplying Russia with medicines
Received revenues in Russia in 2021, there is no any official announcement
Continuing business in Russia and exports, increased revenue and profit in 2022 vs 2021.
Continue doing business as usual, increased revenue in 2022 vs 2021.
Chiesi Group plans to maintain operations in the Russian territories, focusing primarily on medical information and disease awareness and ensure access to our therapeutic options. Chiesi Group is however temporarily pausing any new recruitment of patients for all ongoing clinical trials in Russia, though continuing to treat all those already enrolled and ensuring they receive all the therapeutic solutions they need. "Our focus will always remain on our patients, and Chiesi will continue to prioritise uninterrupted access to treatments to patients in Ukraine and Russia and surrounding territories, despite the unstable situation."
Received revenues in Russia in 2021, there is no any official announcement
Still operating and actively hiring
No official statement
Received revenues in Russia in 2021, there is no any official announcement
Received revenues in Russia in 2021, there is no any official announcement
Received revenues in Russia in 2021, there is no any official announcement
Received revenues in Russia in 2021, there is no any official announcement
Received revenues in Russia in 2021, there is no any official announcement
Received revenues in Russia in 2021, there is no any official announcement
Received revenues in Russia in 2021, there is no any official announcement
Received revenues in Russia in 2021, there is no any official announcement
Received revenues in Russia in 2021, there is no any official announcement
No official statement
The company continues to operate in Russia.
Still operating in Russia
Received revenues in Russia in 2021, there is no any official announcement
No official statement
Received revenues in Russia in 2021, there is no any official announcement
Received revenues in Russia in 2021, there is no any official announcement
Received revenues in Russia in 2021, there is no any official announcement
Still operating in Russia.
Received revenues in Russia in 2021, there is no any official announcement
Received revenues in Russia in 2022.
No statement made regarding Russian operations, Operating out of its office in Moscow
Last year, Belupo achieved sales of 230 million kunas in the markets of Eastern Europe (mainly in Russia), which is 4.1 percent more than the year before, that is, before the Russian aggression.
The US has imposed export restrictions on 37 companies, nearly 30 of them Chinese, for activities that include aiding the Russian military and supporting China's PLA. The restrictions affected divisions of the Chinese genetics company BGI and the Chinese cloud computing company Inspur.
Received revenues in Russia in 2021, there is no any official announcement
EuBiologics signed another technology transfer agreement and contract to supply raw materials for its meningococcal quadrivalent vaccine to Nanolek, a Russian biopharmaceutical.
The complex regulations gave US firms an advantage enabling companies like General Electric Healthcare to actually increase export volumes to Russia, replacing European competitors.
No statement made regarding Russian operations. Continues to operate out of its office in Russia supplying chemical free medicine. Deputy Country Manager at Herbion Russia is still working and is responsible for the business development in Volga Region.
The company continues to work in Russia. It is satisfied with the robot in both countries, as well as in Ukraine and Russia.
"Petrovax," formerly owned by Vladimir Potanin's "Interros" until last year, has reached an agreement with the Chinese company Jiangsu Hengrui regarding the supply and subsequent localization of several oncology drugs, including camrelizumab, belonging to the same class as the American MSD's "Keytruda."
The company supplies its productions to its partners in Russia (LLC "NDA Business Medical Company" and LLC "Firma "Finko").
The Chinese manufacturer of tomographs MinFound registers its products in Russia, and R-Pharm, founded by Alexey Repik, can handle its distribution.
NanoString Technologies is a key distributor and evader of international sanctions regarding the sale and distribution of biotech research equipment.
Received revenues in Russia in 2021, there is no any official announcement
Russian subsiduary OCTAFARMA-PHARMIMEX LLC is active, they are building a pharmaceutical enterprise "Octapharma-Pharmimex" in the Skopinsky district of the Ryazan region.
Despite sanctions and other risks related to business with Russia, many Latvian companies still export to this country. Recently, the Central Statistical Bureau (CSB) published a list of businesses continuing exports to Russia after the war began. Latvian pharmaceuticals giant Olainfarm is also on the list, whose turnover data for 2022 are not available. Olainfarm sent LTV a plan to enter new markets while emphasizing that it's allowed to export medicines to Russia.
The Russian authorities are discussing the possibility of introducing barrier duties of 220% on dietary supplements from unfriendly countries. The measure may affect such large manufacturers as Stada, Solgar, Unipharm, Pharmamed.
The company continues its business in Russia (via PRO.MED.CS Marketing LLC or ТОВ "ПРО.МЕД.ЦС Маркетинг") as it was before and keeps low profile.
Continue operations with Russia.
The company Sentro Group acquired a controlling stake in the Russian bank "Mir Privilege". Sentro Group bought 50.001% of the bank's shares, the transaction amount is not disclosed.
The Russian authorities are discussing the possibility of introducing barrier duties of 220% on dietary supplements from unfriendly countries. The measure may affect such large manufacturers as Stada, Solgar, Unipharm, Pharmamed.
The American company Eli Lilly will transfer its Russian business to the Swiss company Swixx Biopharma. Previously, Swixx Biopharma received the business of another American pharmaceutical company, Bristol-Myers Squibb (BMS).
One of the most popular antiviral drugs in Russia, Valenti Pharm's "Ingavirin", which is included in the treatment protocols for the coronavirus, may have the first generic in Russia. Its release is planned by "Basis-Metygreens" together with the Indian Synmedic.
The Russian authorities are discussing the possibility of introducing barrier duties of 220% on dietary supplements from unfriendly countries. The measure may affect such large manufacturers as Stada, Solgar, Unipharm, Pharmamed.
The American company Varian, which supplies used Truebeam linear accelerators for radiation therapy to Russian oncology clinics, is now required to obtain an export license from the US authorities, a process that takes a minimum of three months.
Had a plant in Russia right before invasion, sell their medicines and never made statements about invasion or the cessation of its activities.
Stopping all non-essential business in Russia and Belarus, while ensuring continued access to health and agriculture products. In this regard, the company decided to continue supplying agricultural products to Russian farmers. Bayer added that it expects Russian authorities to help protect the free flow of agricultural products, expressing the hope that they will not use the food to put pressure on other countries.
The company suspended all advertising, enrollment in clinical trials, and any additional investment in Russia. It was decided to suspend supply of the personal care products in Russia. The company will continue to supply the medicines and medical devices in the region. Suppliers of Johnson & Johnson goods began to send notices to opticians about the suspension of imports.
Pause all new capital investments, media advertising and other promotions; pause new clinical trials and enrollment of new patients
The company suspends non-essential business activity in the country, including all new investments, business development and advertising. So far, the only product (treatment of diabetes) left on the Russian market is the American Abbott.
Pause new site activation and patient enrollment; continue operating